Ranibizumab for the treatment of diabetic retinopathy
Volume: 21, Issue: 8, Pages: 991 - 997
Published: May 19, 2021
Abstract
Introduction: Diabetic retinopathy (DR) is the most common microvascular complication of diabetes mellitus and the leading cause of blindness in young adults. Prior to anti-vascular endothelial growth factor (anti-VEGF) agents, the treatment of DR was based on control of systemic factors and laser photocoagulation. Over the past decade, the use of anti-VEGF agents has revolutionized the treatment of DR, including diabetic macular edema...
Paper Details
Title
Ranibizumab for the treatment of diabetic retinopathy
Published Date
May 19, 2021
Volume
21
Issue
8
Pages
991 - 997
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History